 Allergan Inc formally rejected a  billion unsolicited takeover bid made by Valeant Pharmaceuticals International Inc saying the proposal substantially undervalues the Botox maker Allergan Chief Executive David Pyott defended his companys aggressive researchand development and salesandmarketing spending which he said had enabled Allergan to launch several new products in recent years and increase annual sales by an average of  since   